Cagent Vascular announced on May 21 the completion of a $41 million Series D financing round, as well as the first successful human-use cases with its Serranator SONIC Intravascular Lithotripsy (IVL) System.
The company said the new funding round was co-led by U.S. Venture Partners and Astoria Health Investors. The proceeds will be used to support the global REMODEL II pivotal trial and commercial launch of the SONIC IVL System. Additional funds will also go toward advancing Cagent Vascular’s SONIC IVL coronary artery platform.
According to Cagent Vascular, its Serranator portfolio is already sold in most major U.S. markets and select international markets. The company describes itself as a leader in endovascular technologies focused on improving vessel preparation and treatment outcomes for patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI).
Cagent Vascular stated that it is “the first and only company to commercialize an angioplasty balloon featuring integrated serrations.” The company said it aims to redefine balloon angioplasty through Serration Remodeling Therapy.
The announcement highlights Cagent Vascular’s continued efforts to expand its technology offerings for vascular intervention, as well as its intention to advance clinical trials supporting broader commercialization.
